<!-- <div class="hidden-reset-btn"></div> --> 
<div class="discover-view disease-state-a study-design-a1-bg view progress-full">

<!-- <h1 class="discover-text text-center">
<span style="font-size: 40px;">TAP SCREEN TO START</span>
<br>or
<br>SCROLL LEFT OR RIGHT TO SELECT A VIDEO
</h1> -->

<!-- <div class="white-overlay"></div>
 -->	
 <div class="home-btn">
	<span>
		<img src="images/incyte-home-btn.png" alt="HOME" title="HOME">
	</span>
</div>
	 <div class="goback-btn nav-button develop loads-page" data-pagelink="rationale-b">
		<span>
			<img src="images/ashe-incyte-back-btn.png" alt="" title="">
		</span>
	</div>



	<div class="container-fluid sd-main">
		<h2 class="text-center phaseonetwo">Phase 1/2 Study of INCB039110 (JAK1 Inhibitor) in Combination With Ibrutinib in Subjects<br class="hideSP"> With Relapsed or Refractory Diffuse Large B-cell Lymphoma</h2>
		<div class="col-xs-3 text-center">
			<div class="col-xs-12 bg-blue primary-objectives-nav">

				<h4 class="absolute-center"><img src="images/ash-incyte-check-blue.png"><br>STUDY OBJECTIVES</h4>
			</div>
			<div class="col-xs-12 study-design-nav">
				<h4 class="absolute-center"><img src="images/ash-incyte-pencil-blue.png"><br>STUDY DESIGN</h4>
			</div>
			<div class="col-xs-12 criteria-nav b">
				<h4 class="absolute-center"><img src="images/ash-incyte-key-blue.png"><br>KEY INCLUSION &amp;
				<br>EXCLUSION CRITERIA</h4>
			</div>
		</div>

		<!-- PRIMARY OBJECTIVES -->
		<div class="col-xs-9 primary-obj">
			<div class="chevron-container top">
				<img class="chevron-top" src="images/ashe-incyte-chevron.png">
			</div>




			<div class="sd-main-content">
				<!-- section 1 -->
				<div class="scroll-wrapper" style="position: relative;">
				<br class="showDTOnly"><br class="showDTOnly"><br class="showDTOnly">
					<div id="poB">
						<h3>Phase 1 primary objective:</h3>
						<ul>
						<li>Evaluate the safety and tolerability of INCB039110 in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)</li>
						</ul>
						<h3>Phase 2 primary objective:</h3>
						<ul>
						<li>Evaluate efficacy of INCB039110 in combination with ibrutinib in subjects with R/R non-germinal center B-cell DLBCL as demonstrated by ORR</li>
						</ul>
						<h3>Phase 2 secondary objectives:</h3>
						<ul>
						<li>Evaluate efficacy in terms of DOR, durable response rate, PFS, and OS</li>
						<li>Evaluate safety and tolerability of treatment combination</li>
						</ul>
<br class="showDTOnly">
<br class="showDTOnly">
<br class="showDTOnly">
					</div>

					<!-- section 2 -->
					<div id="sdB">
					<br><br class="showDTOnly">
						<h3>Study Design</h3>
						<img class="img-responsive" src="images/ash-incyte-study-design-graphic-2.png">
						<hr>
<!-- 						<p class="tiny-text">The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p>
 --><br class="showDTOnly">
<br class="showDTOnly">
<br class="showDTOnly">					
					</div>
					

					<!-- section 3 -->
					<div id="kiecB">
						<h3>Key inclusion criteria:</h3>
						<ul>
							<li>Age ≥18 years</li>
							<li>R/R histologically document DLBCL with 1-3 prior treatment regimens
								<ul>
									<li>For phase 1, any DLBCL subtype</li>
									<li>For phase 2, ABC or unclassifiable subtypes of DLBCL</li>
								</ul>
							</li>
							<li>Fluorodeoxyglucose-avid disease per the Lugano Classification<sup>1</sup></li>
							<li>Eastern Cooperative Oncology Group performance status 0 to 2</li>
						</ul>
						<br>
						<h3>Key exclusion criteria:</h3>
						<ul>
							<li>Transformed DLBCL or DLBCL with coexistent histologies (eg, follicular or mucosa-associated
   lymphoid tissue lymphoma)</li>
							<li>Primary mediastinal (thymic) large B-cell lymphoma</li>
							<li>Known central nervous system lymphoma (either primary or metastatic)</li>
							<li>Prior autologous or allo-HSCT, or active graft-versus-host-disease following allo-HSCT</li>
							<li>Prior or concurrent therapy with a JAK inhibitor, Bruton’s tyrosine kinase inhibitor,  or lenalidomide (phase 2 only)</li>
						</ul>
					</div>
				</div>
			</div>


<!-- 			<div class="sd-main-content two absolute-center">

			</div>


			<div class="sd-main-content three absolute-center">

			</div> -->

			<div class="liaison-box text-center">
				<h6>To learn if any of your patients might be eligible for participation in these studies or <br class="hideDTshowBelowSurface">to learn more about becoming an investigator, please speak with one of our Medical Science Liaisons.</h6>
				<p>The efficacy and safety of the investigational compounds discussed have not been established. <br class="hideDTshowBelowSurface">There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p>
			</div>


			<div class="chevron-container btm">
				<img class="chevron-btm" src="images/ashe-incyte-chevron.png">
			</div>
		</div>



	</div>




	<div class="container-fluid text-center absolute-bottom">
		<div class="video-on">
			<div class="col-xs-12">
				<div class="col-xs-2">
					<!-- <img class="discover-play-pause-btn" src="images/ashe-incyte-pause-btn.png">
					<img class="rewind-btn" src="images/ashe-incyte-rewind-btn.png"> -->
				</div>
				<div class="col-xs-9">
<!-- 					<progress id="progressbar" max="100" value="0">
						<div class="progressbar2">
					        <span style="width: 80%;">Progress: 80%</span>
					    </div>
				    </progress> -->
			    </div>
				<div class="col-xs-1">
			   		<img class="popup-btn" src="images/ashe-incyte-popup-btn.png">
			    </div>
			</div>
	    </div>

	    <div class="col-xs-4">
	    	<p class="well nav-button disease-state-b loads-page" data-pagelink="disease-state-b">DLBCL: Disease State</p>
	    </div>

	    <div class="col-xs-4">
	    	<p class="well nav-button rationale-b loads-page" data-pagelink="rationale-b">STUDY RATIONALE</p>
	    </div>

	    <div class="col-xs-4">
	    	<p class="well bg-blue">STUDY DESIGN</p>
	    </div>
	</div>

</div>


<div class="pop-up-div studydesign">
	<ol>
		<li>Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. <i>J Clin Oncol</i>. 2014;32(27):3059-3068.</li>
	</ol>
</div>
<!-- VIDEOS -->
<!-- <div id="video_pop"></div>
 -->
<!-- NAVIGATION -->
<!-- <aside class="side-nav"></aside>
 -->

<!-- <script>
  $(document).ready(function() {  
  		 $("#carousel-home").swiperight(function() {  
    		  $(this).carousel('prev');  
	    		});  
		   $("#carousel-home").swipeleft(function() {  
		      $(this).carousel('next');  
	   });  
	});  
</script>